ORIGINAL RESEARCH article

Front. Endocrinol., 02 November 2012

Sec. Experimental Endocrinology

Volume 3 - 2012 | https://doi.org/10.3389/fendo.2012.00130

Meta-Type Analysis of Dopaminergic Effects on Gene Expression in the Neuroendocrine Brain of Female Goldfish

  • JT

    Jason T. Popesku 1* †

  • CJ

    Christopher J. Martyniuk 2

  • VL

    Vance L. Trudeau 1*

  • 1. Centre for Advanced Research in Environmental Genomics, Department of Biology, University of Ottawa Ottawa, ON, Canada

  • 2. Canadian Rivers Institute and Department of Biology, University of New Brunswick Saint John, NB, Canada

Abstract

Dopamine (DA) is a major neurotransmitter important for neuroendocrine control and recent studies have described genomic signaling pathways activated and inhibited by DA agonists and antagonists in the goldfish brain. Here we perform a meta-type analysis using microarray datasets from experiments conducted with female goldfish to characterize the gene expression responses that underlie dopaminergic signaling. Sexually mature, pre-spawning [gonadosomatic index (GSI) = 4.5 ± 1.3%] or sexually regressing (GSI = 3 ± 0.4%) female goldfish (15–40 g) injected intraperitoneally with either SKF 38393, LY 171555, SCH 23390, sulpiride, or a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and α-methyl-p-tyrosine. Microarray meta-type analysis identified 268 genes in the telencephalon and hypothalamus as having reciprocal (i.e., opposite between agonism and antagonism/depletion) fold change responses, suggesting that these transcripts are likely targets for DA-mediated regulation. Noteworthy genes included ependymin, vimentin, and aromatase, genes that support the significance of DA in neuronal plasticity and tissue remodeling. Sub-network enrichment analysis (SNEA) was used to identify common gene regulators and binding proteins associated with the differentially expressed genes mediated by DA. SNEA analysis identified gene expression targets that were related to three major categories that included cell signaling (STAT3, SP1, SMAD, Jun/Fos), immune response (IL-6, IL-1β, TNFs, cytokine, NF-κB), and cell proliferation and growth (IGF1, TGFβ1). These gene networks are also known to be associated with neurodegenerative disorders such as Parkinsons’ disease, well-known to be associated with loss of dopaminergic neurons. This study identifies genes and networks that underlie DA signaling in the vertebrate CNS and provides targets that may be key neuroendocrine regulators. The results provide a foundation for future work on dopaminergic regulation of gene expression in fish model systems.

Introduction

Dopamine (DA) is a neurotransmitter important in disorders such as schizophrenia (Seeman and Kapur, 2000) and Parkinson’s disease (Baik et al., 1995), but is also the major neurotransmitter controlling teleost reproduction (reviewed in Dufour et al., 2005; Dufour et al., 2010). In this regard, DA inhibits the release of luteinizing hormone (LH) in fish through multiple mechanisms: (a) DA inhibits gonadotropin-releasing hormone (GnRH) release from GnRH neurons through the D1 receptor (Yu and Peter, 1992); (b) DA directly inhibits LH release from gonadotrophs in the anterior pituitary through the D2 receptor (Peter et al., 1986; Omeljaniuk et al., 1987); (c) DA decreases the expression of GnRH receptor mRNA in the pituitary (Kumakura et al., 2003; Levavi-Sivan et al., 2004); and (d) DA inhibits the synthesis of GABA (Hibbert et al., 2004, 2005), an important stimulator of LH release (Martyniuk et al., 2007). Furthermore, it is well understood that DA, acting through the D1, stimulates growth hormone in fish (Wong et al., 1992). Our recent studies using goldfish have investigated the effects of DA agonists on the hypothalamic transcriptome and proteome (Popesku et al., 2010) or of DA antagonists on gene expression in the neuroendocrine brain (Popesku et al., 2011a). Additionally, we have previously described the effects of a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; a selective DA neurotoxin) and α-methyl-p-tyrosine (αMPT; a tyrosine hydroxylase inhibitor) on the goldfish hypothalamic transcriptome (Popesku et al., 2008). Using microarray datasets from two of these experiments, and an additional novel microarray data presented here, we further elucidate the mechanistic effects of DA on gene expression in the neuroendocrine brain by performing a meta-type analysis of these datasets.

In transcriptomics, there are a number of bioinformatics approaches to globally assess gene expression data and to organize expression data into a larger biological context. These methods include Gene Ontology (GO) characterization, functional enrichment, and pathway analysis. Many of these approaches have been successfully performed using genomic data in neuroendocrine regions of teleost fishes to better describe cellular events that are mediated by neurotransmitters, hormones, or exogenous neuroactive agents (Marlatt et al., 2008; Popesku et al., 2008; Zhang et al., 2009a; Martyniuk et al., 2010). New bioinformatics tools are now available to construct gene networks using gene expression profiling and have been used successfully in teleost fish (e.g., reverse engineering of adverse pathways for ecotoxicology (Perkins et al., 2011). Sub-network enrichment analysis (SNEA; Ariadne’s Pathway Studio v7.0 Sivachenko et al., 2007) offers a unique approach to protein interaction networks that are described in the literature as well as a curated mammalian database. Specifically, SNEA builds sub-networks by mapping experimental data onto known bio-molecular interactions. The interactions include promoter-binding, protein modification, and common targets of expression. This algorithm has been used to identify gene sub-networks in breast cancer cell lines (Chuang et al., 2007) and is a useful tool for identifying interaction or signaling networks that involve differentially expressed genes. As such, this method can provide insight in gene regulatory pathways.

In this study, we identify genes and sub-networks that are likely regulated by DA based on their reciprocal response to DA agonism or antagonism/depletion. These data have implications for our understanding of DA action in fish neuroendocrine systems.

Materials and Methods

This is a meta-type analysis of published experiments involving treatments of goldfish with DA agonists (Popesku et al., 2010), antagonists (Popesku et al., 2011a), and after pharmacological depletion of DA (Popesku et al., 2008). The abbreviated Materials and Methods pertaining to the experiments are included here for completeness. It should be noted that, while published, the previous DA depletion studies offered only a cursory analysis of the microarray data in the context of neurotransmitter effects on gene expression and did not specifically address global dopaminergic control of transcriptional responses. Furthermore, we present novel transcriptomic data for specific DA antagonism for which the physiological response to these antagonists has been published (Popesku et al., 2011a), but for which microarray analysis was not performed at that time. We used this novel dataset to compare these DA antagonism responses to agonist and DA depletion responses to improve identification of DA-regulated transcripts in the hypothalamus.

Experimental animals and conditions

All procedures used were approved by the University of Ottawa Protocol Review Committee and followed standard Canadian Council on Animal Care guidelines on the use of animals in research.

Common adult female goldfish were purchased from a commercial supplier (Aleong’s International Inc., Mississauga, ON, Canada) and maintained at 18°C under a natural simulated photoperiod on standard flaked goldfish food. Fish were allowed to acclimate for a minimum of 1 month prior to any experimental manipulations. Goldfish were anesthetized using 3-aminobenzoic acid ethylester (MS222) for all handling, injection, and dissection procedures.

Dopamine agonist experiment

Sexually mature, pre-spawning [mid-May; gonadosomatic index (GSI) = 4.5 ± 1.3%] female goldfish (15–40 g) were injected intraperitoneally with either SKF 38393 [D1 agonist; SKF; 1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol] or LY 171555 [D2 agonist; LY; (−)-Quinpirole hydrochloride] purchased from Tocris (Ballwin, MO, USA). The experimental design and doses chosen were based on Otto et al. (1999) who showed rapid effects on goldfish brain somatostatin mRNAs. LY was dissolved in physiological saline (0.6% NaCl) to yield a dose of 2 μg/g body weight of fish. SKF was first dissolved in a minimal amount of dimethylsulfoxide (DMSO), and subsequently diluted to 40 μg/g body weight of fish with physiological saline (0.6% for fish). The final concentration of DMSO was 0.099%; DMSO up to 0.1% does not affect basal GH or LH levels (Otto et al., 1999). While 0.1% DMSO may (Mortensen and Arukwe, 2006) or may not (Nishimura et al., 2008) affect gene expression, all of our gene expression work is relative to control fish which received an equivalent amount of DMSO. The fish received two sequential i.p. injections at 5 μL/g body weight each according to the schedule shown in Table 1. The experiment was conducted this way to ensure that all fish received an equivalent volume of vehicle.

Table 1

Treatmenti.p. Injection 1i.p. Injection 2# Fish injected
Control0.1% DMSO/saline0.6% Saline13
SKFSKF 38393 40 μg/g0.6% Saline14
LY0.1% DMSO/salineLY 171555 2 μg/g11

Injection schedule for the administration of dopamine agonists used in this study.

Dopamine antagonist experiment

The DA D1-specific antagonist SCH 23390 and DA D2-specific antagonist sulpiride were purchased from Tocris (Ballwin, MO, USA). The antagonists were first dissolved in a minimal amount of DMSO, and subsequently diluted with 0.6% saline. The final concentration of DMSO was 0.099%. Sexually regressing (June; GSI = 3 ± 0.4%; n = 18 each) female goldfish received a single injection at 5 μL/g body weight of either SCH 23390 or sulpiride to give a dose of 40 μg/g or 2 μg/g body weight of fish, respectively, or saline containing an equivalent amount of DMSO.

Dopamine depletion experiment

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and α-methyl-p-tyrosine (αMPT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sexually mature (May; GSI = 4.7 ± 0.6%) female goldfish (n = 5 each) were injected with MPTP (50 μg/g; day 0) and αMPT (240 μg/g; day 5) or saline (control) in order to severely deplete catecholamines. Our previous work had established effective doses of MPTP and αMPT in goldfish (Trudeau et al., 1993; Hibbert et al., 2004).

Tissue dissections

Fish were sacrificed by spinal transection and hypothalami and telencephali tissues were rapidly dissected and immediately frozen on dry ice. Brain tissues were pooled (2–3 hypothalami or telencephali/tube) to increase RNA yield prior to RNA isolation. For the agonists and antagonists, tissues were harvested 5 h post-injection, and for the DA depletion experiment, tissues were harvested 20 h after the αMPT injection. The cerebellae of the fish from the DA depletion experiment were also harvested for brain catecholamine levels, but were not used in further analyses.

RNA isolation, quantification, and quality assessment

RNA was isolated with the TRIzol method (Invitrogen, Burlington, ON, Canada) per the manufacturer’s protocol. Samples were treated with DNase on-column in an RNeasy Mini Plus kit (Qiagen, Mississauga, ON, Canada). RNA quantity was evaluated using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). RNA integrity was evaluated using the BioAnalyzer (Agilent); RIN for each sample was >8.4.

HPLC analysis of brain catecholamine levels in the dopamine depletion experiment

Catecholamine levels in brain tissues were determined on alumina-extracted samples (100 μL) using HPLC with electrochemical detection (Woodward, 1982). The HPLC incorporated a Varian ProStar 410 solvent delivery system (Varian Chromatography Systems, Walnut Creek, CA, USA) coupled to a Princeton Applied Research 400 electrochemical detector (EG & G Instruments, Princeton, NJ, USA). Concentrations were calculated relative to appropriate standards, using 3,4-dihydroxybenzalamine hydrobromide (DHBA) as an internal standard.

Microarray hybridizations

For all microarray analyses, cDNA was synthesized from 2 μg total RNA according to the Genisphere 3DNA Array 900MPX kit according to the manufacturer’s protocol (Genisphere, Hatfield, PA, USA). We previously described and validated the production and use of our goldfish-carp cDNA microarray (Martyniuk et al., 2006; Marlatt et al., 2008; Mennigen et al., 2008), and a detailed description of the microarray is available (Williams et al., 2008). Four microarray hybridizations were performed for each hypothalamic and telencephalic tissue pool for both D1 and D2 agonists (total of 16 arrays), antagonists (16 arrays), or DA depletion (MPTP + αMPT; eight arrays) to screen for the effects of the DA in the neuroendocrine brain. For each experiment, three separate pools of RNA from treated fish were hybridized to the microarrays, and a fourth hybridization was a replicate dye-reversal of one of the three RNA pooled samples. Hybridizations were carried out relative to a common pool of control samples (∼30 control fish) for each tissue, which decreases technical variation as only one reference is utilized while maintaining biological variation of the treatment samples (Churchill, 2002). All cDNA synthesis, labeling, and hybridizations were performed using the Genisphere 3DNA Array 900MPX kit according to the manufacturer’s protocol (Genisphere, Hatfield, PA, USA). Hybridizations and scanning protocols were described previously (Martyniuk et al., 2006; Marlatt et al., 2008; Mennigen et al., 2008). Briefly, microarrays were scanned at full-speed 10-μm resolution with the ScanArray 5000 XL system (Packard Biosciences/PerkinElmer, Woodbridge, ON, Canada) using both red and blue lasers. Images were obtained with ScanArray Express software using automatic calibration sensitivity varying photomultiplier (PMT) gain (PMT starting at 65% for Cy5 and 70% for Cy3) with fixed laser power at 80% and the target intensity set for 90%. Microarray images were analyzed with QuantArray (Packard Biosciences/Perkin Elmer), and raw signal intensity values were obtained for duplicate spots of genes. Raw intensity values for all microarray data and microarray platform information have been deposited in the NCBI Gene Expression Omnibus database and assigned the following SuperSeries accession numbers: GSE15855 (agonists), GSE15763 (antagonists), and GSE16044 (MPTP + αMPT). Generalized Procrustes Analysis (Xiong et al., 2008) was used for normalization of the array data and the Significance Analysis of Microarrays (SAM) method (Woodward, 1982; Tusher et al., 2001) was used to identify differentially expressed genes. Genes/ESTs were selected based on identical AURATUS GeneIDs and on the basis of differential regulation in opposite directions for MPTP or the antagonists vs. agonists, or in the same direction for MPTP vs. antagonists; genes that did not fall into one of these categories were not included in the analysis. All genes/ESTs identified and presented were statistically significant (q < 5%) in all treatments.

Real-time PCR

Primers used in this study for aromatase B, 18S, and β-actin have been validated and published (Martyniuk et al., 2006). The Mx3005 Multiplex Quantitative PCR System (Stratagene, La Jolla, CA, USA) was used to amplify and detect the transcripts of interest. Each PCR reaction contained the following final concentrations: 25 ng first strand cDNA template, 1 ×  QPCR buffer, 3 mM MgCl2, 300 nM each F & R primers, 0.25 ×  SYBRGreen (Invitrogen), 200 μM dNTPs, 1.25 U HotStarTaq (Invitrogen), and 100 nM ROX reference dye, in a 25 μL reaction volume. The thermal cycling parameters were an initial one cycle Taq activation at 95°C for 10 min, followed by 40 cycles of 95°C for 30 s, 59°C for 45 s, and 72°C for 30 s. After the reaction was complete, a dissociation curve was produced starting from 55°C (+1°C/30 s) to 95°C. Dilutions of cDNA (1:10–1:31,250) from all samples were used to construct a relative standard curve for each primer set, relating initial template copy number to fluorescence and amplification cycle. For each PCR reaction, negative controls were also introduced including a no-template control (NTC) where RNase-free water was added to the reaction instead of the template (cDNA) and NoRT control, where water was added instead of reverse transcriptase during cDNA synthesis. The SYBR green assay for each target gene was optimized for primer concentration and annealing temperature to obtain, for the standard curve, an R2 > 0.99, amplification efficiency between 90 and 110% and a single sequence-specific peak in the dissociation curve. No amplification was observed in the NoRT or NTC controls indicating no genomic or reagent contamination. Data were analyzed with the MxPro v4.01 software package.

Sub-network enrichment analysis of reciprocally DA-regulated transcripts

Pathway Studio 7.1 (Ariadne, Rockville, MD, USA) and ResNet 7.0 were used for SNEA for genes that showed reciprocal expression with MPTP-mediated DA depletion and with the DA agonist SKF 38393. We selected the agonist and DA depletion datasets from the hypothalamus for this analysis because (1) the experiments were conducted at the same time of year (May) and (2) these experiments resulted in the greatest number of reciprocal gene expression changes. A total of 114 genes were successfully mapped to human homologs using the GenBank protein ID while 14 genes could not be confidently mapped to human homologs; hence the unmapped proteins were not included in the analysis. SNEA for expression targets, binding partners, and post-translation modification targets was performed to determine if there were common gene targets for MPTP and SKF treatments. SNEA creates a central “seed” from all relevant entities in the database, to find common effectors (expression targets, binding partners, and post-translational targets). The enrichment p-value for gene seeds was set at p < 0.05 and, for the current study, the criteria of greater than five members per group were required for inclusion as a significantly regulated gene network. This was chosen to focus the analysis and discussion on the most likely gene networks regulated through DA signaling.

Results

Catecholamine depletion

To ensure that the MPTP + αMPT treatment effectively decreased DA levels in the brain, Hyp, Tel, and cerebellum (Cer) tissues were analyzed for catecholamine content using HPLC. Following injections of MPTP (−6 days) and αMPT (−1 day), DA levels were decreased by 69.6 and 70.9% in the Hyp and Tel, respectively, and by 88.2% in the Cer relative to saline-injected controls (Figure 1). Norepinephrine (NE) levels were also reduced in the Hyp (79.4%), Tel (87.5%), and Cer (90.4%).

Figure 1

Microarray analysis

Using the microarray datasets from our previous experiments (Popesku et al., 2008, 2010), and the novel microarray data from the antagonist experiment, a meta-type analysis of genes likely regulated by DA was performed. A total of 268 genes/ESTs were identified in the hypothalamus as being regulated by DA, while only four were identified in the telencephalon. Of the 268 genes/ESTs identified in the hypothalamus, only 41% are annotated (Figure A1 in Appendix). The others currently have no known biological function (6%), are not similar to any sequences in GenBank (34%), or are lacking sequence information (19%). The relatively high number of sequences affected by DA in the hypothalamus, the majority of which are acting through the D1 receptor (Table 2), highlights the importance of this receptor in this tissue. The annotated sequences were binned into their corresponding GO Slim terms, using Blast2GO as described in Popesku et al., 2010; Figure 2).

Table 2

TissueAURATUS IDBest blast hitAccessionHuman homolog
DA depletion or receptor blockage
DA mimic
AccessionGeneMPTP + aMPTSCHsulpirideSKFLY
Hyp08j1314 kDa apolipoproteinCF662566No homolog−1.51.7
Hyp08b2217-Beta hydroxysteroid dehydrogenase type 12B, 3-ketoacyl-CoA reductase type BCA968619NM_016142HSD17B121.4−1.7
Hyp16j1426s Protease regulatory subunit 4CA966407NM_002802PSMC1−1.41.4
Hyp08e1440S Ribosomal protein S27CA968660NM_001030RPS27−1.51.7
Hyp07f01Abhydrolase domain containing 12CA967283NM_001042472ABHD12−1.61.8
Hyp22n08Adenylate kinase 3-like 1CA969490NM_016282AK31.3−1.5
Hyp08k20Aldehyde dehydrogenase 7 family, member A1CA968758NM_001182ALDH7A1−1.31.3
Hyp03h23Aldolase CDY231930NM_005165ALDOC1.4−1.6
Hyp05f06Alpha-2-macroglobulin-1CF662428NM_000014A2M−1.61.52.1
Hyp22i24Alpha-actinCA969403NM_001100ACTA11.4−1.5
Hyp09p02AngiotensinogenCA964907NM_000029AGT−1.51.81.3
Hyp09j02Apolipoprotein a-ivCA966743NM_000482APOA4−1.51.7
Hyp16n14Apolipoprotein eCF662778NM_000041APOE−1.32.4
Hyp04a17Aromatase bFG392770NM_000103CYP19A11.3−1.7
Hyp14k14arp2 Actin-related protein 2 homologCA964468NM_005722ACTR2−1.32.31.3
Hyp12l13asf1 Anti-silencing function 1 homolog b (cerevisiae)CA966040NM_018154ASF1B−1.31.9
Hyp16l15atp-Binding sub-family f member 2CA966450NM_007189ABCF2−1.31.6
Hyp16o14BC-10 proteinCA966992NM_006698BLCAP−1.31.9
Hyp03o22Beta-actinDY232011NM_001101ACTB1.3−1.6
Hyp22l24Branched chain ketoacid dehydrogenase kinaseCA969461NM_005881BCKDK1.6−1.8
Hyp02a23Calmodulin 1bFG392553no homolog1.2−1.7
Hyp14g01Claudin 23CA964745NM_194284CLDN23−1.41.8
Hyp14k02Coiled-coil domain containing 47CA964457NM_020198CCDC47−1.32.1
Hyp19a04Cold shock domain-containing protein e1CA964993NM_001007553CSDE1−1.41.51.3
Hyp08o15Complement C3-H2CA970421NM_000064C3−1.41.6
Hyp08b20Complement component q subcomponent-like 4CA968617NM_001008223C1QL4−1.31.3
Hyp02c23Creatine kinase b variant 1DY231608NM_001823CKB1.3−1.6
Hyp02n10Creatine testis isozymeDY231690NM_001824CKM1.2−1.5
Hyp21l19C-type lectinCA969207no homolog1.5−1.7−1.7
Hyp19a14Cubilin (intrinsic factor-cobalamin receptor)CA964997NM_001081CUBN−1.41.4
Hyp17g09Cxxc finger 1 (phd domain)CA964951NM_001101654CXXC11.3−1.7
Hyp06d13Cytochrome P450 2F2-likeCA965416NM_007817CYP2F2−1.41.6
Hyp05l01Cytokine induced apoptosis inhibitor 1CA966987NM_020313CIAPIN1−1.42.3
Hyp03f23Deoxyribonuclease I-like 3DY231911NM_004944DNASE1L31.5−1.5
Hyp23k24e3 Ubiquitin protein ligaseCA968074NM_007013WWP11.6−1.6
Hyp02i24EpendyminDY231713NM_017549EPDR11.3−1.6
Hyp03o21EpendyminDY232010NM_017549EPDR11.4−1.7
Hyp24a12eph Receptor a7CA969719NM_004440EPHA71.6−2.1
Hyp15a10Equilibrative nucleoside transporter 1CA965545NM_001078174SLC29A11.3−1.6
Hyp07b01Eukaryotic translation elongation factor-1 gammaCA966738NM_001404EEF1G−1.51.7
Hyp20j14Eukaryotic translation initiation factor 2, subunit 1 alphaCA966561NM_004094EIF2S1−1.3−2.02.3
Hyp09e01Fibronectin 1bCA964120NM_212482FN1−1.32.01.3
Hyp24j21fk506-Binding protein 1aCA966789NM_054014FKBP1A1.3−1.5
Hyp03o09Fructose-bisphosphate aldolase cFG392624NM_005165ALDOC1.4−1.6
Hyp10m11g Protein-coupled family group member cCA967701NM_024051GGCT1.3−1.6
Hyp17n11Gamma-glutamyl cyclotransferaseCA965786NM_024051GGCT1.3−1.7
Hyp03i20Glutamine synthetaseDY231974NM_001033044GLUL1.2−1.5
Hyp10d04Glutathione peroxidase 3CA964192NM_002084GPX31.4−1.5
Hyp23o12Glyceraldehyde 3-phosphate dehydrogenaseCA968103NM_002046GAPDH2.0−2.1
Hyp08h01Glyceronephosphate-O-acyltransferaseCA968696NM_014236GNPAT−1.62.2
Hyp14b13Granulin 1CA964295NM_002087GRN−1.31.5
Hyp19m14h2a Histone member y2CA965061NM_018649H2AFY2−1.41.6
Hyp14k03Heat shock protein 90 betaCA964458NM_007355HSP90AB1−1.31.7
Hyp14i04HECT domain containing 1CA964417NM_015382HECTD1−1.41.5
Hyp24o12Hexokinase ICA969997NM_000188HK11.6−1.9
Hyp08g14High-density lipoprotein binding proteinCA968690NM_005336HDLBP−1.41.6
Hyp19d02Hydroxysteroid (17-beta) dehydrogenase 10CA965806NM_001037811HSD17B10−1.32.21.3
Hyp03i10Immunoglobulin mu heavy chainFG392590XM_003120441LOC1005106781.5−1.5
Hyp04j23Jumonji domain containing 3FG392963NM_001080424KDM6B1.3−1.5
Hyp13o14LatexinCF662717NM_020169LXN−1.71.6
Hyp22g07Leucine-rich repeat (in flii) interacting protein 1CA969350NM_001137550LRRFIP11.2−1.7
Hyp11p01Leucine-rich repeat containing 58CF662658NM_001099678LRRC58−1.32.2
Hyp19f13Loc548392 proteinCA969104unknown−1.42.0
Hyp14m01Malate dehydrogenase 1, NAD (soluble)CA964750NM_005917MDH1−1.31.81.3
Hyp12k14Male-specific proteinCA970272NM_001012241MSL1−1.31.9
Hyp22o11Map microtubule affinity-regulating kinase 4CA969512NM_031417MARK41.5−2.0
Hyp21l16Membrane palmitoylatedCA966525NM_002436MPP11.9−1.61.3
Hyp09p22Methylcrotonoyl-coenzyme a carboxylase 2CA964915NM_022132MCCC21.5−1.8
Hyp22k08MHC class I antigenCA969424unknown1.4−2.0
Hyp08a03mid1 Interacting g12-like proteinCA970376NM_021242MID1IP1−1.31.6
Hyp09k02mid1 Interacting g12-like proteinCA964854NM_021242MID1IP1−1.41.7
Hyp08l01Middle subunitCA965449NM_002032FTH1−1.42.5
Hyp03k10Midkine-related growth factor bFG392604no homolog1.4−1.5
Hyp12n01Mitochondrial ribosomal protein l19CA966046NM_014763MRPL19−1.61.5
Hyp19p16Mitochondrial ribosomal protein l20CA967272NM_017971MRPL20−1.42.0
Hyp11j11Mitogen-activated protein kinase 7 interacting protein 3CF662634NM_003188MAP3K71.4−1.7
Hyp12p13m-Phase phosphoprotein 6CA966058NM_005792MPHOSPH6−1.52.1
Hyp06g06Myelocytomatosis oncogene bCF662485NM_002467MYC1.3−2.7
Hyp14n02Myosin regulatory light chainCA964520NM_013292MYLPF−1.31.6
Hyp24b19nck Adaptor protein 2CA969746NM_003581NCK21.4−1.5
Hyp19l18Negative elongation factor dCA965844NM_198976TH1L−1.81.5
Hyp03i12Nel-like protein 2FG392591NM_001145107NELL21.3−1.7
Hyp16k15nlr Card domain containing 3CF662774NM_178844NLRC3−1.31.8
Hyp18c18Nol1 nop2 sun domain member 2CA964613NM_017755NSUN2−1.5−1.5
Hyp08o01Novel proteinCA968809no homolog−1.41.5
Hyp11d07Novel proteinCF662614no homolog1.3−1.5
Hyp15i06Novel protein (zgc:136439)CA965636no homolog−1.61.6
Hyp15b13Novel protein lim domain only 3 (rhombotin-like 2; zgc:110149)CA965552NM_001001395LMO3−1.42.0
Hyp11e15Novel sulfotransferase family protein (cytosolic sulfotransferase)CA965939NM_001055SULT1A1−1.31.9
Hyp19e01Nuclear receptor sub-family group member 2CA966183NM_005126NR1D2−1.42.1
Hyp15e23Phosducin-like 3CA966723NM_024065PDCL31.5−1.6
Hyp12l11Plasma retinol-binding protein 1CA966039NM_006744RBP41.3−1.5
Hyp03k09Poplar cDNA sequencesFG392603no homolog1.3−1.5
Hyp08g04Prostaglandin h2 d-isomeraseCA968684NM_000954PTGDS−1.51.5
Hyp22p03Proteasome (macropain) 26s non-4CA969527NM_002810PSMD41.4−1.6
Hyp12b01Proteasome (macropain) alpha 5CA965983NM_002790PSMA5−1.52.01.3
Hyp12i01Purine nucleoside phosphorylaseCA967769NM_000270PNP−1.51.6
Hyp22b23Response gene to complement 32CA969259NM_014059C13orf151.3−2.0
Hyp22g21Ribosomal protein l13CA969362NM_000977RPL131.5−1.7
Hyp08o16Ribosomal protein l27aCA968817NM_000990RPL27A−1.31.5
Hyp12d13Ribosomal protein l27aCA965998NM_000990RPL27A−1.51.6
Hyp09o01Serine incorporator 1CA964172NM_020755SERINC1−1.41.5
Hyp21a01sh3-Domain grb2-like 2CA967895NM_003025SH3GL1−1.51.71.3
Hyp09g14si:ch211-ProteinCA964823no homolog−1.41.8
Hyp24i19StAR-related lipid transfer (START) domain containing 4CA969885NM_139164STARD41.4−2.11.6
Hyp09n02Sterol-c5-desaturase (fungal delta-5-desaturase) homolog (cerevisiae)CA964885NM_006918SC5DL−1.32.5
Hyp12p21Surfeit 4CA966062NM_033161SURF4−1.51.6
Hyp20o02Tetraspanin 9CA965906NM_006675TSPAN9−1.61.6
Hyp24i22Transaldolase 1CA969888NM_006755TALDO11.4−1.6
Hyp15f10Translocon-associated protein subunit delta precursorCA965601NM_006280SSR41.3−1.8
Hyp12f01Transthyretin precursorCA966004NM_000371TTR−1.33.0
Hyp07h01Triosephosphate isomeraseCA968504NM_000365TPI1−1.31.8
Hyp14f24Troponin c-type 2CA964383NM_003279TNNC21.4−2.1
Hyp21g17Troponin c-type 2CA967929NM_003279TNNC2−1.51.6
Hyp22g09Tubulin alpha 8 like 4CA969352NM_006082TUBA1B1.3−1.8
Hyp03o23Tubulin beta-2cFG392672NM_006088TUBB2C1.4−1.5
Hyp17j23Tubulin beta-2c chainCA965774NM_006088TUBB2C1.4−1.5
Hyp14f02u2 Small nuclear RNA auxiliary factor-1CA964363NM_006758U2AF1−1.72.41.3
Hyp22l09Vacuolar protein sorting 13cCA969449NM_018080VPS13C1.3−1.5
Hyp20j02Vacuolar protein sorting 4aCA966560NM_013245VPS4A−1.51.71.6
Hyp14j12VimentinCA964445NM_003380VIM1.4−1.5
Hyp24i24VimentinCA969890NM_003380VIM1.4−1.7
Hyp12i13Vitellogenin 2CA967775no homolog−1.31.4
Hyp19o08Zinc and double phd fingers family 2CA965067NM_006268DPF2−1.51.5
Hyp23a24Zinc finger ccch-type containing 7aCA967982NM_017590ZC3H7B2.0−2.3
Hyp15i14Zinc finger protein 782CA965639NM_001001662ZNF782−1.32.0
Hyp20c13Zona pellucida glycoproteinCA966260no homolog−1.61.7
Tel12o17ccaat Enhancer-binding protein betaCA967804NM_005194CEBPB−1.61.7
Tel12e10Leucine-rich ppr-motif containingCA970240NM_133259LRPPRC−1.81.6
Tel14f04Solute carrier family 2 (facilitated glucose fructose transporter) member 5CA964365NM_207420SLC2A7−1.31.9

Genes/ESTs identified as regulated by dopamine, presented as fold-changes.

ESTs were manually selected based on identical AURATUS GeneIDs and on the basis of differential regulation in opposite directions for MPTP or the antagonists vs. agonists, or in the same direction for MPTP vs. antagonists. All ESTs were identified as being differentially regulated (q < 5%) in all treatments. Only those with BLAST hits (NCBI), obtained with Blast2GO, are shown. Duplicate names may exist in the list, but were not identified by sequence overlap (cap3) and may represent separate genes or individual isoforms. The median “minimum ExpectValue” = 1.9E−57 and the average “mean similarity” = 84.8% ± 1%. In the case where a suitable BlastX hit was unavailable, the best BlastN hit is used and is listed in the complete table in the supplemental data (Table A1 in Appendix). SCH, SCH 23390; SKF, SKF 38393; LY, LY 171555.

Figure 2

Real-time RT-PCR validation of AromB

Changes in the hypothalamic mRNA levels of Aromatase B identified by microarray analysis were validated using real-time RT-PCR. Figure 3 shows a 4.7-fold decrease (p = 0.027) in AromB mRNA levels 5 h post-injection with SKF 38393. AromB mRNA levels were increased 1.6-fold following DA depletion, but did not reach statistical significance (p > 0.05).

Figure 3

SNEA

Sub-network enrichment analysis identified a number gene set targets for MPTP-mediated DA depletion and SKF 38393 (Table 3). Expression targets of insulin (INS) were highly affected by DA deletion and receptor stimulation (Figure 4A). This expression group included genes such as apoe and apoa4, vim, gapdh, and myc. Expression targets also affected by DA depletion and SKF 38393 were those related to cell signaling, for example expression targets of STAT3, SMAD, JUN, and SP1 signaling. A second major group of expression targets included those related to inflammation such as cytokines, NF-κB, IL-6, IL-1β, and TNF. Genes involved in cytokine signaling that are reciprocally affected by dopaminergic stimulation/inhibition included fn1, cyp19a1, psmd4, vim, and glul (Figure 4B). The third group involved expression targets related to cell growth and differentiation such as insulin-like growth factor I (IGF1) and transforming growth factor-beta (TGFβ1; Figure 4C). Also noteworthy was that expression targets of HIF1A were also identified in the SNEA analysis (Table 3). SNEA is also able to identify binding partner networks and post-translational targets using differentially expressed genes. Binding partners of vitamin D, GAPDH, myosin, and tubulin were affected by treatments while protein modification targets of trypsin and glutathione transferase were significantly impacted through DA signaling (Table 3).

Figure 4

Table 3

NameGene set seedOverlapping entitiesp-Value
Expression targetsINSAGT, FN1, MYC, GAPDH, GLUL, GPX3, APOE, TTR, VIM, C3, APOA4, A2M, ACTB, FTH1, CKM, BCKDK1.37E−06
STAT3FN1, MYC, VIM, APOA4, A2M, HSP90AB1, CYP19A1, C13orf156.46E−04
PGRFN1, MYC, GAPDH, CYP19A1, C13orf151.02E−03
SP1AGT, FN1, MYC, APOE, VIM, C3, SLC29A1, CYP19A1, SH3GL1, SULT1A1, ASF1B, CKM, BCKDK, CKB, CYP2F11.21E−03
NR3C1AGT, FN1, MYC, GAPDH, GLUL, CYP19A1, SULT1A11.43E−03
JUNFN1, MYC, GLUL, APOE, VIM, A2M, CYP19A1, TPI11.48E−03
AKT1FN1, MYC, GAPDH, MAP3K7, VIM, A2M, CYP19A1, CKM2.10E−03
CEBPAAGT, MYC, GAPDH, GLUL, TTR, C3, APOA4, ACTB3.63E−03
SMADFN1, MYC, VIM, C13orf15, CKM3.92E−03
IGF1AGT, FN1, MYC, VIM, FKBP1A, CYP19A1, TUBA1B, ACTB4.86E−03
SMAD3FN1, MYC, VIM, CYP19A1, CKM5.56E−03
HGFFN1, MYC, EIF2S1, VIM, C3, A2M5.59E−03
SRCFN1, MYC, A2M, CYP19A1, PSMD46.62E−03
CytokineFN1, MYC, PTGDS, GLUL, APOE, TTR, VIM, C3, APOA4, A2M, CYP19A1, CIAPIN1, PSMD46.86E−03
HIF1AFN1, MYC, GAPDH, VIM, SLC29A1, PSMD47.38E−03
PI3KFN1, MYC, MAP3K7, FKBP1A, SLC29A1, HSP90AB1, CYP19A1, CKM8.94E−03
NF−kBFN1, MYC, PTGDS, GAPDH, GLUL, GRN, APOE, VIM, C3, A2M, CYP19A18.97E−03
TP53AGT, FN1, MYC, PTGDS, GAPDH, SLC29A1, HSP90AB1, CKM, PSMD49.81E−03
Jun/FosFN1, MYC, PTGDS, APOE, TTR, VIM, A2M, CYP19A1, TPI11.12E−02
STATAGT, FN1, MYC, C3, A2M1.55E−02
CTNNB1FN1, MYC, GLUL, VIM, PSMD41.67E−02
PKCFN1, MYC, PTGDS, GLUL, GRN, APOE, HSP90AB1, CYP19A11.69E−02
IL-6FN1, MYC, APOE, TTR, A2M, HSP90AB1, CYP19A1, CKM1.71E−02
EndotoxinPTGDS, GAPDH, APOE, A2M, ACTB2.32E−02
IL-1βFN1, PTGDS, VIM, C3, A2M, HSP90AB1, ACTB, FTH12.35E−02
IFNGAGT, FN1, MYC, GAPDH, APOE, VIM, C3, A2M, HSP90AB1, TUBA1B2.96E−02
TNFAGT, FN1, MYC, PTGDS, GAPDH, GLUL, APOE, VIM, C3, CYP19A1, ACTB3.75E−02
EP300AGT, FN1, GAPDH, HSP90AB1, CKM4.67E−02
TGFB1FN1, MYC, APOE, VIM, SLC29A1, CYP19A1, ACTB, C13orf15, CKM, RPS274.86E−02
LEPFN1, MYC, GAPDH, APOA4, CYP19A14.91E−02
Binding partnersVitamin DC3, APOA4, CUBN, ACTA12.81E−05
GAPDHFN1, GAPDH, FKBP1A, TUBA1B7.44E−04
HDLFN1, TTR, A2M, HDLBP1.36E−03
APPFN1, TTR, A2M, HSD17B101.92E−03
MyosinGAPDH, VIM, ACTB, MPP13.63E−03
TubulinMAP3K7, APOE, TPI1, HK1, LRPPRC, EEF1G5.21E−03
ATPMAP3K7, APOE, HSP90AB1, MCCC24.82E−02
Protein modification targetsTrypsinAGT, FN1, GLUL, VIM, C3, A2M4.39E−03
GSTVIM, FKBP1A, TALDO1, NSUN28.28E−03

Sub-network enrichment analysis groupings of genes identified as being regulated by dopamine.

Discussion

Our approach is an effort to identify a group of genes that are likely regulated by DA. The principle behind the analysis is that genes commonly affected in one direction by severe catecholamine depletion (MPTP + αMPT) and/or DA antagonists will also be affected by DA agonists but expression changes will be in the opposite direction. The power and novelty of this analysis lies in the physiological manipulation and biological validation of reciprocal fold-changes between DA agonists and antagonists/depletion in vivo, rather than the technical validation resulting from different techniques performed on the same samples. Additionally, we validated the expression of brain aromatase in the hypothalamus (discussed below) using real-time RT-PCR.

Here we present transcripts that are affected by well-characterized dopaminergic manipulations and allow for speculation on DAergic mechanisms of action in the goldfish neuroendocrine brain. Furthermore, our analysis identified gene networks and provides the foundation for future work on DAergic regulation of neuroendocrine gene expression. Some of the genes/ESTs identified in this analysis (e.g., calmodulin, apolipoprotein) were previously discussed (Popesku et al., 2010) and will not be discussed here. It is not our intention to examine all of the genes/ESTs listed in Table 2, but we have selected some to discuss in terms of current and emerging ideas in dopaminergic neuron (dys)function. The genes/ESTs below are discussed relative to DA receptor stimulation.

The DA agonists and the DA depletion experiments provided the greatest number of reciprocal changes in gene expression compared to the DA antagonist experiment, which is likely due to the fact that both the agonist and depletion experiments were conducted at the same time of year (May) when the fish were of similar sexual maturity (GSI ∼4.6%) compared to the antagonist experiment (June) when fish were sexually regressing (GSI ∼3%). The difference in the number of gene changes between these time points highlights the importance of seasonality of dopaminergic action in the neuroendocrine brain of fish (Zhang et al., 2009b). Indeed, the inhibitory tone of DA on gonadotropin release at these times of year indicate that the fish are in different physiological states (Trudeau et al., 1993; Vacher et al., 2002) and thus may respond to DAergic manipulation differently. This is apparent in some of the genes listed in Table 2 (full list in Table A1 in Appendix), and is a limitation of our approach. We are, however, comparing the effects of DAergic manipulation against paired control fish and are looking for genes that are consistently differentially expressed as a result of that manipulation. While few genes were differentially expressed in the DA antagonist experiment when compared to the other two datasets, the new microarray data presented here provides some further insight into teleost brain function.

Norepinephrine levels were severely reduced in addition to DA levels in MPTP + αMPT-treated fish; however, the genes discussed below are limited to those showing opposite changes to specific DA agonists supporting the hypothesis that genes are therefore likely regulated by DA itself.

The identification of ependymin and vimentin in the hypothalamus highlights the significance of neuronal plasticity and tissue remodeling in response to DAergic manipulations. Ependymin is an extracellular glycoprotein and neurotrophic growth factor involved in optic nerve regeneration, synaptic plasticity, and long-term potentiation in Cypriniformes (Shashoua, 1991; Adams and Shashoua, 1994; Adams et al., 1996). Moreover, ependymin was shown to be overexpressed in regenerating echinoderms (Suarez-Castillo et al., 2004). Ependymin-related proteins were identified in amphibians and mammals (Suarez-Castillo and Garcia-Arraras, 2007) and Shashoua et al. (2001) showed that a short fragment of goldfish ependymin was able to activate the AP-1 transcription factor in neuroblastoma and primary rat brain cortical cultures. Similarly, vimentin is an intermediate filament and is known to increase during cerebellar regeneration in the brown ghost knifefish, Apteronotus leptorynchus (Clint and Zupanc, 2002). At least 2 forms of vimentin exist in goldfish (Glasgow et al., 1994), and while the current analysis is unable to resolve the form(s) of vimentin regulated by DA, it is likely that both of the sequences listed in Table 2 correspond to the same form, as they share nearly identical expression patterns in response to DA. Both vimentin and ependymin, along with α- and β-actin and tubulins (Table 2) were decreased in response to DA, supporting the role of DA in synaptic plasticity and tissue remodeling (Kauer and Malenka, 2007). Cytoskeletal remodeling is hypothesized to be important for hormone secretion from the anterior pituitary in mammals (Ravindra and Grosvenor, 1990). Furthermore, Ravindra and Grosvenor (1988) demonstrated that domperidone, a D2-specific antagonist that does not cross the blood-brain barrier but can act on the pituitary, increased prolactin (PRL) levels as well as pituitary polymerized tubulin levels, similar to levels seen in suckling rats. This response, the authors observed, was blocked by bromocriptine, a D2-specific agonist supporting a role for DA in changes observed in the tubulin system in the anterior pituitary. This is relevant because, in fish, it should be noted that DAergic neurons in the mediobasal hypothalamus (e.g., posterior tuberculum) project directly to the pituitary (i.e., are hypophysiotropic; Hornby and Piekut, 1990; Anglade et al., 1993). This is important as it suggests the need for maintaining DA neuronal populations throughout seasonal reproductive period. The identification of aromatase b (CYP19B, or AroB) in our analysis as being inhibited by DA is of particular interest. Our RT-PCR targeted validation of the decrease in AroB mRNA levels in response to SKF 38393, it also confirmed an opposite change in direction of AroB mRNA levels in response to DA depletion as identified by the microarray. In adult fish, AroB is expressed only in radial glial cells (Diotel et al., 2010; Le Page et al., 2010), which persist throughout life and serve as neuronal progenitors in the brain. At least some AroB-immunoreactive (ir) neurons in the medial preoptic area (POA) of the Japanese quail brain respond to DA (Cornil et al., 2004) and a few AroB-ir neurons in the POA of the bluehead wrasse are in close proximity with, while a subset appear to co-express, tyrosine hydrolase (TH; Marsh et al., 2006), the rate-limiting step in DA synthesis and a marker for cathecholaminergic neurons. Moreover, some TH-ir neurons in the POA of rainbow trout express estrogen receptors (Linard et al., 1996) and testosterone and estradiol increase goldfish pituitary DA turnover rates as measured following αMPT-induced catecholamine depletion (Trudeau et al., 1993). More importantly, DA was shown to reduce aromatase enzyme activity in quail POA homogenates in vitro (Baillien and Balthazart, 1997). These studies, including the current one, suggest that DA regulates AroB, possibly to modulate the feedback mechanisms of sex steroids on the brain. However, AroB is also important in neurogenesis and brain repair (reviewed in Diotel et al., 2010). Interestingly, Pollard et al. (1992) showed full recovery of DA levels in the brain of goldfish after 8 days using a moderate dose of MPTP (50 μg/g), and Poli et al. (1992) demonstrated spontaneous recovery of DA and NE levels in the goldfish telencephalon, diencephalon, and medulla after 6 weeks following injection of MPTP at a lower dose (10 μg/g) for three consecutive days. These two studies suggest that in fish, unlike in mammals, DA neurons regenerate following injection with MPTP, and may be linked to higher aromatase activity in the fish brain. This is an avenue of research we are currently conducting.

Multiple genes/ESTs identified as being regulated by DA are involved in the lipid and fatty acid metabolic process or transport. For example, 17β-hydroxysteroid dehydrogenase type 12B (HSD17B12; down), high-density lipoprotein binding protein (HDLBP; up), vitellogenin 2 (vtg2; up), cubulin (CUBN; up), sh3-domain grb-like 2 (SH3GL1; up), StAR-related lipid transfer domain containing 4 (STARD4; down), and sterol-c5-desaturase homolog (SC5DL; up) were identified as being regulated by DA. SC5D is involved in the biosynthesis of cholesterol (Sugawara et al., 2001). HSD17B12 reduces 3-ketoacyl-CoA to 3-hydroxyacyl-CoA in the second step of fatty acid elongation (Moon and Horton, 2003). In vivo studies in zebrafish demonstrated that HDLBP is not affected by the insulin family or growth hormone, but it is hypothesized that HDLBP is involved in lipid transfer based on its high expression in the liver and ovary (Chen et al., 2003). CUBN is a high-density lipoprotein receptor (Moestrup and Kozyraki, 2000) and STARD4 is hypothesized to facilitate transport of a cholesterol precursor (Soccio et al., 2002). Vtg is best characterized as a liver phosphoprotein stimulated by estrogen and then deposited in the ovary (Jalabert, 2005; Kang et al., 2007), but is, in general, a lipid transport molecule. The changes in these mRNAs suggest lipid mobilization, possibly to derive energy for neuronal remodeling as discussed above.

The granulins are conserved growth factors and are able to stimulate the proliferation of macrophages in goldfish (Hanington et al., 2006). Granulin also has protease inhibitor activity in invertebrates (Hong and Kang, 1999) and cysteine protease activity in plants (Chen et al., 2006). Granulin was shown to be relatively lowly expressed in the brain of goldfish (Hanington et al., 2006) and tilapia (Chen et al., 2007). It appears as though DA, acting through the D1 receptor, stimulates expression of granulin in the hypothalamus of female goldfish. In the developing rat hypothalamus, it was demonstrated that both estrogen and androgen induced granulin expression (Suzuki et al., 2001) and that estrogen induced granulin expression in the dentate gyrus (hippocampus) of adult rats (Chiba et al., 2007). Furthermore, in hippocampal rat tissue in vitro, estradiol enhanced neural progenitor cell proliferation and this response was blocked by a granulin-specific antibody (Chiba et al., 2007). Although speculative, this is relevant, as hydroxysteroid (17β) dehydrogenase was identified here as being increased in response to DA, which interconverts 17β-estradiol and estrone, 16-α-hydroxyestrone and estriol, and androstenedione and testosterone Stoffel-Wagner (2003), suggesting that sex steroids influence the DAergic regulation of granulin or, alternatively, the DA modulates estrogen-regulated granulin expression.

Granulin mRNA levels were also identified as being decreased 4.2-fold in the goldfish telencephalon following a 2-days waterborne exposure to 0.1 μM thyroid hormone (T3; Wiens, 2009). While unconfirmed, this is intriguing because the current study identified transthyretin (TTR) mRNA levels as being significantly increased in response to DA. TTR is a thyroid hormone-binding and transport protein and is necessary for maintaining normal levels of circulating thyroid hormone in plasma (Episkopou et al., 1993). Furthermore, TTR protein levels are increased in the cerebrospinal fluid (CSF) of rats with degenerating nigrostriatal neurons (Rite et al., 2007). Future studies aimed at examining the potential interaction between T3 and DA are warranted, particularly as microarray analysis identified increases in mRNA levels of iodothyronine deiodinase type I in the hypothalamus of female fish in response to SKF 38393 and 171555 (D1- and D2-specific agonists, respectively; Popesku et al., 2010).

The identification of U2 small nuclear RNA auxiliary factor-1 (U2AF1) mRNA levels as being increased by DA acting through the D1 receptor (Table 2) is interesting. There are currently five known small nuclear ribonucleoproteins (snRNPs) that make up the spliceosome (Query, 2009). LSM7 protein, whose mRNA levels were also increased in both DA agonist treatments (Popesku et al., 2010) also forms part of the spliceosome complex (Salgado-Garrido et al., 1999). The increase in both of these factors in response to either DA agonist suggests that blockage of either of these receptors would inhibit transcription of particular components of the spliceosome, and thus decrease splicing activity, thereby decreasing the amount of a particular splice variant. The observed decrease of the D2 short isoform splice variant in response to both D1 and D2 antagonists (Popesku et al., 2011b) supports this hypothesis.

Only three annotated genes/ESTs were identified in the telencephalon that were increased in response to D2 receptor agonists and decreased in response to D2 receptor blockage or DA depletion. This indicates that DA, acting through the D2 receptor, regulates these genes/ESTs. That relatively few genes affected by DA manipulation in the telencephalon was a surprising finding. While we expected tissue-specific responses to the various pharmacological treatments, we may have expected more than three genes to be affected in the Tel. In the case of D2 receptor, mRNA levels are high and specifically but widely expressed in regions of both Hyp and Tel of the African cichlid fish, Astatotilapia burtoni (O’Connell et al., 2011). However, it is not only the expression of receptors that will determine the response to an exogenous pharmacological agent, but also the ongoing effects of endogenous DA levels that are acting on both D1 and D2 receptors in vivo. It is clear in both goldfish and the cichlid, that DAergic innervation in the Hyp and Tel are extensive but clearly different, depending on the specific sub-region of each tissue (Hornby and Piekut, 1990; O’Connell et al., 2011). The clear difference in the global expression patterns in response to the various DA manipulations we report for goldfish Hyp and Tel supports this. Moreover, the type of cells expressing those receptors in each tissue will undoubtedly be different, so we do indeed expect major tissue differences.

Two of the DA-regulated genes/ESTs in the telencephalon are leucine-rich ppr-motif containing protein (LRPPRC) and solute carrier family 2 (facilitated glucose fructose transporter) member 5 (SLC2A5; glucose transporter 5; GLUT5). LRPPRC is a core nucleoid protein (Bogenhagen et al., 2008) and is hypothesized to have a regulatory role in the integration of the cytoskeleton with vesicular trafficking, nucleocytosolic shuttling, transcription, chromosome remodeling, and cytokinesis based on its interactions with other proteins by yeast 2-hybrid analysis (Liu and McKeehan, 2002). The third gene regulated by D2 in the telencephalon, CCAAT/enhancer-binding protein beta (C/EBPβ), is particularly interesting. CaMKII phosphorylates C/EBPβ (Wegner et al., 1992), which, in turn, activates transcription factor-1 (ATF1; Shimomura et al., 1996), among other things. Methamphetamine administration to mice caused a dose-dependent increase in ATF1 and CREB DNA-binding activities (Lee et al., 2002). As CaMKIIα protein levels were increased in response to DA agonists (Popesku et al., 2010), a working hypothesis of DAergic regulation of gene expression in the neuroendocrine brain of goldfish through the increase in ATF1 can thus be put forth.

Sub-network enrichment analysis takes advantage of previously characterized interactions between genes (expression relationships) and proteins (binding relationships). It is also able to associate genes and proteins with cell processes or diseases. The SNEA approach was developed by Ariadne (Pathway Studio®). Briefly, data on molecular interactions are retrieved from the ResNet nine database which is compiled using MedScan. The database contains over 20 million PubMed abstracts and approximately 900 K full-text articles (May 27, 2011). A background distribution of expression values in the gene list is calculated by an algorithm. This is followed by a statistical comparison between the sub-network and the background distribution using a Mann–Whitney U-Test, a p-value is generated that indicates the statistical significance of difference between two distributions (additional details can be found in the technical bulletin pg. 717 from Pathway Studio 7.0). SNEA has similar objectives to Ingenuity Pathway analysis and each is a useful tool to visualize molecular datasets. SNEA is different from KEGG which uses well defined biochemical and molecular pathways. SNEA has been applied in biomarker discovery in mammals (Kotelnikova et al., 2012) and for gene and protein networks in teleost fishes (Martyniuk et al., 2012; Trudeau et al., 2012). For this study, we chose to use Pathway Studios to visualize our data.

There were three major categories of the SNEA identified in the current study: cell signaling (STAT3, SP1, SMAD, Jun/Fos), immune response (IL-6, IL-1β, and TNF, cytokine, NF-κB), and cell proliferation and growth (IGF1, TGFβ1). Inflammatory pathways modulated by DA have been characterized in mouse models and have been associated with degenerative processes and cytokines released from glial cells play important roles in mediating cellular responses to injury due to neurotoxicants such as MPTP. For example, old male and female transgenic mice injected intraperitoneally with MPTP (15 mg/kg for 2 days at two injections/day) caused males to have dramatic increases in IL-1β luciferase reporter gene activity that correlated to the increased susceptibility of dopaminergic neurons to MPTP toxicity found in old male mice (Bian et al., 2009). In the same study, mRNA levels of TNF-α and IL-6 were not changed, but notable here is that genes affected downstream of IL-6 and TNF signaling were altered by DA in the goldfish hypothalamus, suggesting that these signaling cascades can be sensitive to dopaminergic inputs. In support of these data, both mRNA and protein levels for various cytokines (IL-1β, TNF-α, and IL-6) and expression of their receptors were significantly increased in the substantia nigra of MPTP-treated mice (Lofrumento et al., 2011). Here we identify putative gene targets and subsequent genomic effects that may occur after cytokine induction in the vertebrate CNS. A recent review by O’Callaghan et al. (2008) discuss the role of MPTP in inflammation in relation to cytokine signaling, including cytokines identified in the goldfish hypothalamus such as IL-1β and IL-6. Lastly, in regards to the inflammatory response in the goldfish, many of the cell signaling cascades are also involved in the immune response. For example, JAK/STAT3 signaling plays a role in inflammation in the mammalian brain in response to MPTP (Sriram et al., 2004). Therefore, the gene set node for cell signaling molecules (e.g., STAT) identified in the goldfish may directly stimulate inductions in cytokines.

Gene targets of IGF1 and TGFβ were also affected in expression after DA depletion and DA agonism. IGF1 activates RAS, P13K, and AKT signaling pathway to stimulate growth and differentiation of cells. TGF-β is a member of the transforming growth factor family that is involved in cell differentiation and regulation of the immune system. Both these signaling pathways are known to have a role in dopaminergic signaling and to be associated with the onset of neurodegenerative diseases. There are reports to suggest that IGF signaling may be involved in neuroprotection within the CNS. IGF1 has been shown to have protective role in MPP +  induced neurotoxicity in human neuroblastoma SH-EP1 cells by inhibiting apoptotic processes (Wang et al., 2010) and female rats treated with the neurotoxin 6-hydroxydopamine (6-OHDA) did not show reduced tyrosine hydroxylase immunoreactivity (a marker for DA toxicity) after intracerebroventricular infusion of IGF1 substantia nigra compared to those without the treatment (Quesada et al., 2008). The effect of IGF1 was dependent upon the PI3K/Akt pathway. It is plausible that gene expression changes in the goldfish hypothalamus in response to DA depletion and DA receptor activation are protective responses to DA-mediated neurotoxicity. Tong et al. (2009) investigated IGF distribution in human post-mortem brain tissues and report that IGF-I expression was significantly elevated in the frontal cortex of Parkinson’s patients while IGF-II expression was significantly reduced in the frontal white matter of PD patients. Thus, there are complex interactions between different IGF signaling pathways in the neurodegenerative brain (IGF1 and IGF2), however experimental evidence associates IGF in these processes. Similar to IGF1, TGFβ signaling targets are implemented in DA signaling in the goldfish hypothalamus. This pathway has also been implicated in neurodegeneration (Andrews et al., 2006) and the TGFβ signaling pathway can be modulated with DA treatments (Recouvreux et al., 2011).

Fish models are increasingly being used for investigations into the mechanisms of disease occurrence and progression (Weinreb and Youdim, 2007). Here we provide examples and demonstrate the usefulness of implementing SNEA to gain increased insight into key regulators underlying neurotransmitter signaling in the neuroendocrine brain and uncover novel associations between disease states and pharmacological treatments. In so doing, we provide a foundation for future work on dopaminergic regulation of gene expression in fish.

Authors’ Contributions

Jason T. Popesku conceived of the study, designed and carried out the experiments, analyzed the data, and drafted the manuscript. Christopher J. Martyniuk participated in the design of the experiments, performed the sub-network enrichment analysis, and helped draft the manuscript. Vance L. Trudeau helped conceive the individual experiments, participated in the design and coordination of the study, and helped to draft the manuscript. All authors read and approved the final manuscript.

Statements

Acknowledgments

The authors would like to thank B. McNeill and S. F. Perry for performing the HPLC analysis. Jason T. Popesku and Vance L. Trudeau would like to thank the Parkinson’s Research Consortium of Ottawa for financial support. Jason T. Popesku appreciates the support of the Ontario Graduate Scholarship. This research was funded by NSERC Discovery Grants to Vance L. Trudeau and Christopher J. Martyniuk, and a Canadian Research Chair (Christopher J. Martyniuk).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    AdamsD. S.KiyokawaM.GetmanM. E.ShashouaV. E. (1996). Genes encoding giant danio and golden shiner ependymin. Neurochem. Res.21, 377384.10.1007/BF02527762

  • 2

    AdamsD. S.ShashouaV. E. (1994). Cloning and sequencing the genes encoding goldfish and carp ependymin. Gene141, 237241.10.1016/0378-1119(94)90578-9

  • 3

    AndrewsZ. B.ZhaoH.FrugierT.MeguroR.GrattanD. R.KoishiK.et al (2006). Transforming growth factor beta2 haploinsufficient mice develop age-related nigrostriatal dopamine deficits. Neurobiol. Dis.21, 568575.10.1016/j.nbd.2005.09.001

  • 4

    AngladeI.ZandbergenT.KahO. (1993). Origin of the pituitary innervation in the goldfish. Cell Tissue Res.273, 345355.10.1007/BF00312837

  • 5

    BaikJ. H.PicettiR.SaiardiA.ThirietG.DierichA.DepaulisA.et al (1995). Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature377, 424428.10.1038/377424a0

  • 6

    BaillienM.BalthazartJ. (1997). A direct dopaminergic control of aromatase activity in the quail preoptic area. J. Steroid Biochem. Mol. Biol.63, 99113.10.1016/S0960-0760(97)00080-0

  • 7

    BianM. J.LiL. M.YuM.FeiJ.HuangF. (2009). Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice. Brain Res.1302, 256264.10.1016/j.brainres.2009.07.030

  • 8

    BogenhagenD. F.RousseauD.BurkeS. (2008). The layered structure of human mitochondrial DNA nucleoids. J. Biol. Chem.283, 36653675.10.1074/jbc.M708444200

  • 9

    ChenH. J.HuangD. J.HouW. C.LiuJ. S.LinY. H. (2006). Molecular cloning and characterization of a granulin-containing cysteine protease SPCP3 from sweet potato (Ipomoea batatas) senescent leaves. J. Plant Physiol.163, 863876.10.1016/j.jplph.2005.07.006

  • 10

    ChenJ. Y.ChenJ. C.WuJ. L. (2003). Molecular cloning and functional analysis of zebrafish high-density lipoprotein-binding protein. Comp. Biochem. Physiol. B Biochem. Mol. Biol.136, 117130.10.1016/S1096-4959(03)00181-7

  • 11

    ChenM. H.LiY. H.ChangY.HuS. Y.GongH. Y.LinG. H.et al (2007). Co-induction of hepatic IGF-I and progranulin mRNA by growth hormone in tilapia, Oreochromis mossambiccus. Gen. Comp. Endocrinol.150, 212218.10.1016/j.ygcen.2006.08.005

  • 12

    ChibaS.SuzukiM.YamanouchiK.NishiharaM. (2007). Involvement of granulin in estrogen-induced neurogenesis in the adult rat hippocampus. J. Reprod. Dev.53, 297307.10.1262/jrd.18108

  • 13

    ChuangH. Y.LeeE.LiuY. T.LeeD.IdekerT. (2007). Network-based classification of breast cancer metastasis. Mol. Syst. Biol.3, 140.10.1038/msb4100180

  • 14

    ChurchillG. A. (2002). Fundamentals of experimental design for cDNA microarrays. Nat. Genet.32(Suppl. 4), 9095.10.1038/ng0902-90

  • 15

    ClintS. C.ZupancG. K. (2002). Up-regulation of vimentin expression during regeneration in the adult fish brain. Neuroreport13, 317320.10.1097/00001756-200203040-00014

  • 16

    CornilC. A.SeutinV.MotteP.BalthazartJ. (2004). Electrophysiological and neurochemical characterization of neurons of the medial preoptic area in Japanese quail (Coturnix japonica). Brain Res.1029, 224240.10.1016/j.brainres.2004.09.047

  • 17

    DiotelN.Le PageY.MouriecK.TongS. K.PellegriniE.VaillantC.et al (2010). Aromatase in the brain of teleost fish: expression, regulation and putative functions. Front. Neuroendocrinol.31, 172192.10.1016/j.yfrne.2010.01.003

  • 18

    DufourS.SebertM. E.WeltzienF. A.RousseauK.PasqualiniC. (2010). Neuroendocrine control by dopamine of teleost reproduction. J. Fish Biol.76, 129160.10.1111/j.1095-8649.2009.02499.x

  • 19

    DufourS.WeltzienF. A.SebertM. E.LeBelleN.VidalB.VernierP.et al (2005). Dopaminergic inhibition of reproduction in teleost fishes: ecophysiological and evolutionary implications. Ann. N. Y. Acad. Sci.1040, 921.10.1196/annals.1327.002

  • 20

    EpiskopouV.MaedaS.NishiguchiS.ShimadaK.GaitanarisG. A.GottesmanM. E.et al (1993). Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc. Natl. Acad. Sci. U.S.A.90, 23752379.10.1073/pnas.90.6.2375

  • 21

    GlasgowE.DrugerR. K.FuchsC.LevineE. M.GiordanoS.SchechterN. (1994). Cloning of multiple forms of goldfish vimentin: differential expression in CNS. J. Neurochem.63, 470481.10.1046/j.1471-4159.1994.63020470.x

  • 22

    HaningtonP. C.BarredaD. R.BelosevicM. (2006). A novel hematopoietic granulin induces proliferation of goldfish (Carassius auratus L.) macrophages. J. Biol. Chem.281, 99639970.10.1074/jbc.M600631200

  • 23

    HibbertB.FungI.McAuleyR.LariviereK.MacNeilB.Bafi-YeboaN.et al (2004). Increased GAD67 mRNA levels are correlated with in vivo GABA synthesis in the MPTP-treated catecholamine-depleted goldfish brain. Mol. Brain Res.128, 121130.10.1016/j.molbrainres.2004.06.008

  • 24

    HibbertB.FungI.McAuleyR.SamiaM.TrudeauV. (2005). Catecholamine depletion modulates serum LH levels, GAD67 mRNA, and GABA synthesis in the goldfish. Gen. Comp. Endocrinol.140, 176183.10.1016/j.ygcen.2004.11.008

  • 25

    HongS. J.KangK. W. (1999). Purification of granulin-like polypeptide from the blood-sucking leech, Hirudo nipponia. Protein Expr. Purif.16, 340346.10.1006/prep.1999.1077

  • 26

    HornbyP. J.PiekutD. T. (1990). Distribution of catecholamine-synthesizing enzymes in goldfish brains: presumptive dopamine and norepinephrine neuronal organization. Brain Behav. Evol.35, 4964.10.1159/000115856

  • 27

    JalabertB. (2005). Particularities of reproduction and oogenesis in teleost fish compared to mammals. Reprod. Nutr. Dev.45, 261279.10.1051/rnd:2005019

  • 28

    KangB. J.JungJ. H.LeeJ. M.LimS. G.SaitoH.KimM. H.et al (2007). Structural and expression analyses of two vitellogenin genes in the carp, Cyprinus carpio. Comp. Biochem. Physiol. B Biochem. Mol. Biol.148, 445453.10.1016/j.cbpb.2007.07.088

  • 29

    KauerJ. A.MalenkaR. C. (2007). Synaptic plasticity and addiction. Nat. Rev. Neurosci.8, 844858.10.1038/nrn2234

  • 30

    KotelnikovaE.ShkrobM. A.PyatnitskiyM. A.FerliniA.DaraseliaN. (2012). Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLoS Comput. Biol.8, e1002365.10.1371/journal.pcbi.1002365

  • 31

    KumakuraN.OkuzawaK.GenK.KagawaH. (2003). Effects of gonadotropin-releasing hormone agonist and dopamine antagonist on hypothalamus-pituitary-gonadal axis of pre-pubertal female red seabream (Pagrus major). Gen. Comp. Endocrinol.131, 264273.10.1016/S0016-6480(03)00012-1

  • 32

    Le PageY.DiotelN.VaillantC.PellegriniE.AngladeI.MerotY.et al (2010). Aromatase, brain sexualization and plasticity: the fish paradigm. Eur. J. Neurosci.32, 21052115.10.1111/j.1460-9568.2010.07519.x

  • 33

    LeeY. W.SonK. W.FloraG.HennigB.NathA.ToborekM. (2002). Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain. J. Neurosci. Res.70, 8289.10.1002/jnr.10370

  • 34

    Levavi-SivanB.SafarianH.RosenfeldH.ElizurA.AvitanA. (2004). Regulation of gonadotropin-releasing hormone (GnRH)-receptor gene expression in tilapia: effect of GnRH and dopamine. Biol. Reprod.70, 15451551.10.1095/biolreprod.103.021998

  • 35

    LinardB.AngladeI.CorioM.NavasJ. M.PakdelF.SaligautC.et al (1996). Estrogen receptors are expressed in a subset of tyrosine hydroxylase-positive neurons of the anterior preoptic region in the rainbow trout. Neuroendocrinology63, 156165.10.1159/000126952

  • 36

    LiuL.McKeehanW. L. (2002). Sequence analysis of LRPPRC and its SEC1 domain interaction partners suggests roles in cytoskeletal organization, vesicular trafficking, nucleocytosolic shuttling, and chromosome activity. Genomics79, 124136.10.1006/geno.2001.6679

  • 37

    LofrumentoD. D.SaponaroC.CianciulliA.De NuccioF.MitoloV.NicolardiG.et al (2011). MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation18, 7988.10.1159/000320027

  • 38

    MarlattV. L.MartyniukC. J.ZhangD.XiongH.WattJ.XiaX.et al (2008). Auto-regulation of estrogen receptor subtypes and gene expression profiling of 17beta-estradiol action in the neuroendocrine axis of male goldfish. Mol. Cell. Endocrinol.283, 3848.10.1016/j.mce.2007.10.013

  • 39

    MarshK. E.CreutzL. M.HawkinsM. B.GodwinJ. (2006). Aromatase immunoreactivity in the bluehead wrasse brain, Thalassoma bifasciatum: immunolocalization and co-regionalization with arginine vasotocin and tyrosine hydroxylase. Brain Res.1126, 91101.10.1016/j.brainres.2006.09.017

  • 40

    MartyniukC. J.AlvarezS.LoB. P.ElphickJ. R.MarlattV. L. (2012). Hepatic protein expression networks associated with masculinization in the female fathead minnow (Pimephales promelas). J. Proteome Res.11, 41474161.10.1021/pr3002468

  • 41

    MartyniukC. J.ChangJ. P.TrudeauV. L. (2007). The effects of GABA agonists on glutamic acid decarboxylase, GABA-transaminase, activin, salmon gonadotrophin-releasing hormone and tyrosine hydroxylase mRNA in the goldfish (Carassius auratus) neuroendocrine brain. J. Neuroendocrinol.19, 390396.10.1111/j.1365-2826.2007.01543.x

  • 42

    MartyniukC. J.FeswickA.SpadeD. J.KrollK. J.BarberD. S.DenslowN. D. (2010). Effects of acute dieldrin exposure on neurotransmitters and global gene transcription in largemouth bass (Micropterus salmoides) hypothalamus. Neurotoxicology31, 356366.10.1016/j.neuro.2010.04.008

  • 43

    MartyniukC. J.XiongH.CrumpK.ChiuS.SardanaR.NadlerA.et al (2006). Gene expression profiling in the neuroendocrine brain of male goldfish (Carassius auratus) exposed to 17alpha-ethinylestradiol. Physiol. Genomics27, 328336.10.1152/physiolgenomics.00090.2006

  • 44

    MennigenJ. A.MartyniukC. J.CrumpK.XiongH.ZhaoE.PopeskuJ.et al (2008). Effects of fluoxetine on the reproductive axis of female goldfish (Carassius auratus). Physiol. Genomics35, 273282.10.1152/physiolgenomics.90263.2008

  • 45

    MoestrupS. K.KozyrakiR. (2000). Cubilin, a high-density lipoprotein receptor. Curr. Opin. Lipidol.11, 133140.10.1097/00041433-200004000-00005

  • 46

    MoonY. A.HortonJ. D. (2003). Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J. Biol. Chem.278, 73357343.10.1074/jbc.M207789200

  • 47

    MortensenA. S.ArukweA. (2006). Dimethyl sulfoxide is a potent modulator of estrogen receptor isoforms and xenoestrogen biomarker responses in primary culture of salmon hepatocytes. Aquat. Toxicol.79, 99103.10.1016/j.aquatox.2006.05.009

  • 48

    NishimuraM.NikawaT.KawanoY.NakayamaM.IkedaM. (2008). Effects of dimethyl sulfoxide and dexamethasone on mRNA expression of housekeeping genes in cultures of C2C12 myotubes. Biochem. Biophys. Res. Commun.367, 603608.10.1016/j.bbrc.2008.01.006

  • 49

    O’CallaghanJ. P.SriramK.MillerD. B. (2008). Defining “neuroinflammation.”Ann. N. Y. Acad. Sci.1139, 318330.10.1196/annals.1432.032

  • 50

    O’ConnellL. A.FontenotM. R.HofmannH. A. (2011). Characterization of the dopaminergic system in the brain of an African cichlid fish, Astatotilapia burtoni. J. Comp. Neurol.519, 7592.10.1002/cne.22735

  • 51

    OmeljaniukR. J.ShihS. H.PeterR. E. (1987). In-vivo evaluation of dopamine receptor-mediated inhibition of gonadotrophin secretion from the pituitary gland of the goldfish, Carassius auratus. J. Endocrinol.114, 449458.10.1677/joe.0.1140449

  • 52

    OttoC. J.LinX.PeterR. E. (1999). Dopaminergic regulation of three somatostatin mRNAs in goldfish brain. Regul. Pept.83, 97104.10.1016/S0167-0115(99)00052-X

  • 53

    PerkinsE. J.ChipmanJ. K.EdwardsS.HabibT.FalcianiF.TaylorR.et al (2011). Reverse engineering adverse outcome pathways. Environ. Toxicol. Chem.30, 2238.10.1002/etc.374

  • 54

    PeterR. E.ChangJ. P.NahorniakC. S.OmeljaniukR. J.SokolowskaM.ShihS.et al (1986). Interactions of catecholamines and GnRH in regulation of gonadotropin secretion in teleost fish. Recent Prog. Horm. Res.42, 513548.

  • 55

    PoliA.GandolfiO.LucchiR.BarnabeiO. (1992). Spontaneous recovery of MPTP-damaged catecholamine systems in goldfish brain areas. Brain Res.585, 128134.10.1016/0006-8993(92)91197-M

  • 56

    PollardH. B.DhariwalK.AdeyemoO. M.MarkeyC. J.CaohuyH.LevineM.et al (1992). A Parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP. FASEB J.6, 31083116.

  • 57

    PopeskuJ. T.MartyniukC. J.DenslowN. D.TrudeauV. L. (2010). Rapid dopaminergic modulation of the fish hypothalamic transcriptome and proteome. PLoS ONE5, e12338.10.1371/journal.pone.0012338

  • 58

    PopeskuJ. T.MartyniukC. J.MennigenJ.XiongH.ZhangD.XiaX.et al (2008). The goldfish (Carassius auratus) as a model for neuroendocrine signaling. Mol. Cell. Endocrinol.293, 4356.10.1016/j.mce.2008.06.017

  • 59

    PopeskuJ. T.MennigenJ. A.ChangJ. P.TrudeauV. L. (2011a). Dopamine D1 receptor blockage potentiates AMPA-stimulated luteinising hormone release in the goldfish. J. Neuroendocrinol.23, 302309.10.1111/j.1365-2826.2011.02114.x

  • 60

    PopeskuJ. T.Navarro-MartinL.TrudeauV. L. (2011b). Evidence for alternative splicing of a dopamine D2 receptor in a teleost. Physiol. Biochem. Zool.84, 135146.10.1086/658290

  • 61

    QueryC. C. (2009). Structural biology: spliceosome subunit revealed. Nature458, 418419.10.1038/458418a

  • 62

    QuesadaA.LeeB. Y.MicevychP. E. (2008). PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson’s disease. Dev. Neurobiol.68, 632644.10.1002/dneu.20609

  • 63

    RavindraR.GrosvenorC. E. (1988). Soluble and polymerized tubulin levels in the anterior pituitary lobe of the lactating rat during suckling. Endocrinology122, 114119.10.1210/endo-122-1-114

  • 64

    RavindraR.GrosvenorC. E. (1990). Involvement of cytoskeleton in polypeptide hormone secretion from the anterior pituitary lobe: a review. Mol. Cell. Endocrinol.71, 165176.10.1016/0303-7207(90)90022-Z

  • 65

    RecouvreuxM. V.GuidaM. C.RifkinD. B.Becu-VillalobosD.Diaz-TorgaG. (2011). Active and total transforming growth factor-{beta}1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology152, 27222730.10.1210/en.2010-1464

  • 66

    RiteI.ArguellesS.VeneroJ. L.Garcia-RodriguezS.AyalaA.CanoJ.et al (2007). Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res.85, 36073618.10.1002/jnr.21452

  • 67

    Salgado-GarridoJ.Bragado-NilssonE.Kandels-LewisS.SeraphinB. (1999). Sm and Sm-like proteins assemble in two related complexes of deep evolutionary origin. EMBO J.18, 34513462.10.1093/emboj/18.12.3451

  • 68

    SeemanP.KapurS. (2000). Schizophrenia: more dopamine, more D2 receptors. Proc. Natl. Acad. Sci. U.S.A.97, 76737675.10.1073/pnas.97.14.7673

  • 69

    ShashouaV. E. (1991). Ependymin, a brain extracellular glycoprotein, and CNS plasticity. Ann. N. Y. Acad. Sci.627, 94114.10.1111/j.1749-6632.1991.tb25916.x

  • 70

    ShashouaV. E.AdamsD.Boyer-BoiteauA. (2001). CMX-8933, a peptide fragment of the glycoprotein ependymin, promotes activation of AP-1 transcription factor in mouse neuroblastoma and rat cortical cell cultures. Neurosci. Lett.312, 103107.10.1016/S0304-3940(01)02119-X

  • 71

    ShimomuraA.OgawaY.KitaniT.FujisawaH.HagiwaraM. (1996). Calmodulin-dependent protein kinase II potentiates transcriptional activation through activating transcription factor 1 but not cAMP response element-binding protein. J. Biol. Chem.271, 1795717960.10.1074/jbc.271.30.17957

  • 72

    SivachenkoA. Y.YuryevA.DaraseliaN.MazoI. (2007). Molecular networks in microarray analysis. J. Bioinform. Comput. Biol.5, 429456.10.1142/S0219720007002795

  • 73

    SoccioR. E.AdamsR. M.RomanowskiM. J.SehayekE.BurleyS. K.BreslowJ. L. (2002). The cholesterol-regulated StarD4 gene encodes a StAR-related lipid transfer protein with two closely related homologues, StarD5 and StarD6. Proc. Natl. Acad. Sci. U.S.A.99, 69436948.10.1073/pnas.052143799

  • 74

    SriramK.BenkovicS. A.HebertM. A.MillerD. B.O’CallaghanJ. P. (2004). Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?J. Biol. Chem.279, 1993619947.10.1074/jbc.M309304200

  • 75

    Stoffel-WagnerB. (2003). Neurosteroid biosynthesis in the human brain and its clinical implications. Ann. N. Y. Acad. Sci.1007, 6478.10.1196/annals.1286.007

  • 76

    Suarez-CastilloE. C.Garcia-ArrarasJ. E. (2007). Molecular evolution of the ependymin protein family: a necessary update. BMC Evol. Biol.7, 23.10.1186/1471-2148-7-23

  • 77

    Suarez-CastilloE. C.Medina-OrtizW. E.Roig-LopezJ. L.Garcia-ArrarasJ. E. (2004). Ependymin, a gene involved in regeneration and neuroplasticity in vertebrates, is overexpressed during regeneration in the echinoderm Holothuria glaberrima. Gene334, 133143.10.1016/j.gene.2004.03.023

  • 78

    SugawaraT.FujimotoY.IshibashiT. (2001). Molecular cloning and structural analysis of human sterol C5 desaturase. Biochim. Biophys. Acta1533, 277284.10.1016/S1388-1981(01)00160-3

  • 79

    SuzukiM.YonezawaT.FujiokaH.MatuamuroM.NishiharaM. (2001). Induction of granulin precursor gene expression by estrogen treatment in neonatal rat hypothalamus. Neurosci. Lett.297, 199202.10.1016/S0304-3940(00)01699-2

  • 80

    TongM.DongM.de la MonteS. M. (2009). Brain insulin-like growth factor and neurotrophin resistance in Parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J. Alzheimers Dis.16, 585599.

  • 81

    TrudeauV. L.MartyniukC. J.ZhaoE.HuH.VolkoffH.DecaturW. A.et al (2012). Is secretoneurin a new hormone?Gen. Comp. Endocrinol.175, 1018.10.1016/j.ygcen.2011.10.008

  • 82

    TrudeauV. L.SloleyB. D.WongA. O.PeterR. E. (1993). Interactions of gonadal steroids with brain dopamine and gonadotropin-releasing hormone in the control of gonadotropin-II secretion in the goldfish. Gen. Comp. Endocrinol.89, 3950.10.1006/gcen.1993.1007

  • 83

    TusherV. G.TibshiraniR.ChuG. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A.98, 51165121.10.1073/pnas.091062498

  • 84

    VacherC.FerriereF.MarmignonM. H.PellegriniE.SaligautC. (2002). Dopamine D2 receptors and secretion of FSH and LH: role of sexual steroids on the pituitary of the female rainbow trout. Gen. Comp. Endocrinol.127, 198206.10.1016/S0016-6480(02)00046-1

  • 85

    WangL.YangH. J.XiaY. Y.FengZ. W. (2010). Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3beta/JNK signaling. Apoptosis15, 14701479.10.1007/s10495-010-0547-z

  • 86

    WegnerM.CaoZ.RosenfeldM. G. (1992). Calcium-regulated phosphorylation within the leucine zipper of C/EBP beta. Science256, 370373.10.1126/science.256.5055.370

  • 87

    WeinrebO.YoudimM. B. (2007). A model of MPTP-induced Parkinson’s disease in the goldfish. Nat. Protoc.2, 30163021.10.1038/nprot.2007.393

  • 88

    WiensS. C. (2009). Thyroid Hormone Regulation of the Reproductive Neuroendocrine Axis of the Goldfish (Carassius auratus), Department of Biology, University of Ottawa, Ottawa, 180.

  • 89

    WilliamsD. R.LiW.HughesM. A.GonzalezS. F.VernonC.VidalM. C.et al (2008). Genomic resources and microarrays for the common carp Cyprinus carpio L. J. Fish Biol.72, 20952117.10.1111/j.1095-8649.2008.01875.x

  • 90

    WongA. O.ChangJ. P.PeterR. E. (1992). Dopamine stimulates growth hormone release from the pituitary of goldfish, Carassius auratus, through the dopamine D1 receptors. Endocrinology130, 12011210.10.1210/en.130.6.3512

  • 91

    WoodwardJ. J. (1982). Plasma catecholamines in resting rainbow trout, Salmo gairdneri Richardson, by high pressure liquid chromatography. J. Fish Biol.21, 429432.10.1111/j.1095-8649.1982.tb02848.x

  • 92

    XiongH.ZhangD.MartyniukC. J.TrudeauV. L.XiaX. (2008). Using generalized procrustes analysis (GPA) for normalization of cDNA microarray data. BMC Bioinformatics9, 25.10.1186/1471-2105-9-25

  • 93

    YuK. L.PeterR. E. (1992). Adrenergic and dopaminergic regulation of gonadotropin-releasing hormone release from goldfish preoptic-anterior hypothalamus and pituitary in vitro. Gen. Comp. Endocrinol.85, 138146.10.1016/0016-6480(92)90181-I

  • 94

    ZhangD.PopeskuJ. T.MartyniukC. J.XiongH.Duarte-GutermanP.YaoL.et al (2009a). Profiling neuroendocrine gene expression changes following fadrozole-induced estrogen decline in the female goldfish. Physiol. Genomics38, 351361.10.1152/physiolgenomics.00051.2009

  • 95

    ZhangD.XiongH.MennigenJ. A.PopeskuJ. T.MarlattV. L.MartyniukC. J.et al (2009b). Defining global neuroendocrine gene expression patterns associated with reproductive seasonality in fish. PLoS ONE4, e5816.10.1371/journal.pone.0005816

Appendix

Figure A1

Table A1

TissueAURATUS IDBest blast hitDA depletion or receptor blockage
DA mimic
Accession
MPTP + aMPTSCH 23390SulpirideSKF 38393LY171555
Hyp08j1314 kDa Apolipoprotein−1.51.7CF662566
Hyp08b2217-Beta hydroxysteroid dehydrogenase type 12B, 3-ketoacyl-CoA reductase type B1.4−1.7CA968619
Hyp16j1426s Protease regulatory subunit 4−1.41.4CA966407
Hyp08e1440S Ribosomal protein S27−1.51.7CA968660
Hyp07f01Abhydrolase domain containing 12−1.61.8CA967283
Hyp22n08Adenylate kinase 3-like 11.3−1.5CA969490
Hyp08k20Aldehyde dehydrogenase 7 family, member A1−1.31.3CA968758
Hyp03h23Aldolase C1.4−1.6DY231930
Hyp05f06Alpha-2-macroglobulin-1−1.61.52.1CF662428
Hyp22i24Alpha-actin1.4−1.5CA969403
Hyp09p02Angiotensinogen−1.51.81.3CA964907
Hyp09j02Apolipoprotein a-iv−1.51.7CA966743
Hyp16n14Apolipoprotein e−1.32.4CF662778
Hyp04a17Aromatase b1.3−1.7FG392770
Hyp14k14arp2 Actin-related protein 2 homolog−1.32.31.3CA964468
Hyp12l13asf1 Anti-silencing function 1 homolog b (cerevisiae)−1.31.9CA966040
Hyp16l15atp-Binding sub-family f member 2−1.31.6CA966450
Hyp16o14BC-10 protein−1.31.9CA966992
Hyp03o22Beta-actin1.3−1.6DY232011
Hyp22l24Branched chain ketoacid dehydrogenase kinase1.6−1.8CA969461
Hyp02a23Calmodulin 1b1.2−1.7FG392553
Hyp17j08Carassius auratus mRNA for BC-10 protein1.3−1.5CA966515
Hyp10f12Carp DNA sequence from clone carpf-118, complete sequence1.5−1.6CA964207
Hyp16e02Chromosome 9 open reading frame 82−1.41.6CA966153
Hyp14g01Claudin 23−1.41.8CA964745
Hyp14k02Coiled-coil domain containing 47−1.32.1CA964457
Hyp19a04Cold shock domain-containing protein e1−1.41.51.3CA964993
Hyp08o15Complement C3-H2−1.41.6CA970421
Hyp08b20Complement component q subcomponent-like 4−1.31.3CA968617
Hyp02c23Creatine kinase b variant 11.3−1.6DY231608
Hyp02n10Creatine testis isozyme1.2−1.5DY231690
Hyp21l19C-type lectin1.5−1.7−1.7CA969207
Hyp19a14Cubilin (intrinsic factor-cobalamin receptor)−1.41.4CA964997
Hyp17g09cxxc Finger 1 (phd domain)1.3−1.7CA964951
Hyp11i01Cyprinus carpio DN1 mRNA for DNase I, complete cds−1.41.7CA965953
Hyp06d13Cytochrome p450 like−1.41.6CA965416
Hyp05l01Cytokine induced apoptosis inhibitor 1−1.42.3CA966987
Hyp10g12Danio rerio HECT domain containing 1 (hectd1), mRNA1.5−1.5CA967652
Hyp19h04Danio rerio heterogeneous nuclear ribonucleoprotein A/B, mRNA (cDNA clone MGC:55953), complete cds−1.41.8CA965823
Hyp24j13Danio rerio lin-7 homolog A (C. elegans; lin7a), mRNA−1.41.4CA969901
Hyp07m24Danio rerio non-metastatic cells 4, protein expressed in (nme4), mRNA1.4−1.7CA964093
Hyp22c24Danio rerio SET translocation (myeloid leukemia-associated) A (seta), mRNA1.3−1.6CA969283
Hyp08g15Danio rerio zgc:110605 (zgc:110605), mRNA−1.31.6CA970392
Hyp12e04Danio rerio zgc:55886 (zgc:55886), mRNA−1.31.71.3CA966744
Hyp24k14Danio rerio zgc:77060 (zgc:77060), mRNA1.9−1.7CA969922
Hyp22m10Danio rerio zgc:92169 (zgc:92169), mRNA1.3−1.6CA969469
Hyp09b02Danio rerio zgc:92371 (zgc:92371), mRNA−1.42.01.3CA964765
Hyp03j12Danio rerio neuron-specific protein family member 1 (brain neuron cytoplasmic protein 1) mRNA1.3−1.6FG392599
Hyp03f23Deoxyribonuclease I-like 31.5−1.5DY231911
Hyp23k24e3 Ubiquitin protein ligase1.6−1.6CA968074
Hyp02i24Ependymin1.3−1.6DY231713
Hyp03o21Ependymin1.4−1.7DY232010
Hyp24a12eph Receptor a71.6−2.1CA969719
Hyp15a10Equilibrative nucleoside transporter 11.3−1.6CA965545
Hyp07b01Eukaryotic translation elongation factor-1 gamma−1.51.7CA966738
Hyp20j14Eukaryotic translation initiation factor 2, subunit 1 alpha−1.3−2.02.3CA966561
Hyp09e01Fibronectin 1b−1.32.01.3CA964120
Hyp24j21fk506-Binding protein 1a1.3−1.5CA966789
Hyp03o09Fructose-bisphosphate aldolase c1.4−1.6FG392624
Hyp10m11g Protein-coupled family group member c1.3−1.6CA967701
Hyp17n11Gamma-glutamyl cyclotransferase1.3−1.7CA965786
Hyp02g12Gasterosteus aculeatus clone cnb214-a06 mRNA sequence1.3−1.5DY231579
Hyp03i20Glutamine synthetase1.2−1.5DY231974
Hyp10d04Glutathione peroxidase 31.4−1.5CA964192
Hyp23o12Glyceraldehyde 3-phosphate dehydrogenase2.0−2.1CA968103
Hyp08h01Glyceronephosphate-O-acyltransferase−1.62.2CA968696
Hyp14b13Granulin 1−1.31.5CA964295
Hyp19m14h2a Histone member y2−1.41.6CA965061
Hyp14k03Heat shock protein 90 beta−1.31.7CA964458
Hyp14i04HECT domain containing 1−1.41.5CA964417
Hyp24o12Hexokinase I1.6−1.9CA969997
Hyp08g14High-density lipoprotein binding protein−1.41.6CA968690
Hyp19d02Hydroxysteroid (17-beta) dehydrogenase 10−1.32.21.3CA965806
Hyp03i10Immunoglobulin mu heavy chain1.5−1.5FG392590
Hyp04j23Jumonji domain containing 31.3−1.5FG392963
Hyp13o14Latexin−1.71.6CF662717
Hyp22g07Leucine-rich repeat (in flii) interacting protein 11.2−1.7CA969350
Hyp11p01Leucine-rich repeat containing 58−1.32.2CF662658
Hyp19f13loc548392 Protein−1.42.0CA969104
Hyp14m01Malate dehydrogenase 1, NAD (soluble)−1.31.81.3CA964750
Hyp12k14Male-specific protein−1.31.9CA970272
Hyp22o11Map microtubule affinity-regulating kinase 41.5−2.0CA969512
Hyp21l16Membrane palmitoylated1.9−1.61.3CA966525
Hyp09p22Methylcrotonoyl-coenzyme a carboxylase 21.5−1.8CA964915
Hyp22k08MHC class I antigen1.4−2.0CA969424
Hyp08a03mid1 Interacting g12-like protein−1.31.6CA970376
Hyp09k02mid1 Interacting g12-like protein−1.41.7CA964854
Hyp08l01Middle subunit−1.42.5CA965449
Hyp03k10Midkine-related growth factor b1.4−1.5FG392604
Hyp12n01Mitochondrial ribosomal protein l19−1.61.5CA966046
Hyp19p16Mitochondrial ribosomal protein l20−1.42.0CA967272
Hyp11j11Mitogen-activated protein kinase 7 interacting protein 31.4−1.7CF662634
Hyp12p13m-Phase phosphoprotein 6−1.52.1CA966058
Hyp06g06Myelocytomatosis oncogene b1.3−2.7CF662485
Hyp14n02Myosin regulatory light chain−1.31.6CA964520
Hyp24b19nck Adaptor protein 21.4−1.5CA969746
Hyp19l18Negative elongation factor d−1.81.5CA965844
Hyp03i12Nel-like protein 21.3−1.7FG392591
Hyp16k15nlr Card domain containing 3−1.31.8CF662774
Hyp18c18nol1 nop2 Sun domain member 2−1.5−1.5CA964613
Hyp08o01Novel protein−1.41.5CA968809
Hyp11d07Novel protein1.3−1.5CF662614
Hyp15i06Novel protein (zgc:136439)−1.61.6CA965636
Hyp15b13Novel protein lim domain only 3 (rhombotin-like 2) zgc:110149)−1.42.0CA965552
Hyp11e15Novel sulfotransferase family protein−1.31.9CA965939
Hyp19e01Nuclear receptor sub-family group member 2−1.42.1CA966183
Hyp15e23Phosducin-like 31.5−1.6CA966723
Hyp12l11Plasma retinol-binding protein 11.3−1.5CA966039
Hyp03k09Poplar cDNA sequences1.3−1.5FG392603
Hyp12o13PREDICTED: Danio rerio hypothetical LOC560379 (LOC560379), mRNA−1.31.5CA966719
Hyp24d23PREDICTED: Danio rerio hypothetical LOC567058 (LOC567058), mRNA1.3−1.5CA966814
Hyp15i02PREDICTED: Danio rerio hypothetical protein LOC553758 (LOC553758), mRNA−1.31.6CA965635
Hyp19f14PREDICTED: Danio rerio hypothetical protein LOC792300 (LOC792300), mRNA−1.32.5CA965818
Hyp07i10PREDICTED: Danio rerio im:7148349 (im:7148349), misc RNA1.7−1.6CA964049
Hyp08j02PREDICTED: Danio rerio similar to Chromosome 19 open reading frame 43, transcript variant 1 (LOC560758), mRNA−1.52.1CA968727
Hyp19o03PREDICTED: Danio rerio similar to dipeptidyl-peptidase 6, transcript variant 1 (LOC566832), mRNA−1.61.4CA966233
Hyp12o22PREDICTED: Danio rerio similar to histocompatibility 28 (LOC555357), mRNA−1.61.5CA970293
Hyp17g21PREDICTED: H3 histone, family 3B−1.31.8CA964956
Hyp15o14PREDICTED: hypothetical protein [Danio rerio]−1.22.0CA965715
Hyp22g11PREDICTED: hypothetical protein LOC337077, partial [Danio rerio]1.3−2.0CA969354
Hyp08g04Prostaglandin h2 d-isomerase−1.51.5CA968684
Hyp22p03Proteasome (macropain) 26s non- 41.4−1.6CA969527
Hyp12b01Proteasome (macropain) alpha 5−1.52.01.3CA965983
Hyp12i01Purine nucleoside phosphorylase−1.51.6CA967769
Hyp22b23Response gene to complement 321.3−2.0CA969259
Hyp22g21Ribosomal protein l131.5−1.7CA969362
Hyp08o16Ribosomal protein l27a−1.31.5CA968817
Hyp12d13Ribosomal protein l27a−1.51.6CA965998
Hyp09o01Serine incorporator 1−1.41.5CA964172
Hyp04c11Sesbania drummondii clone ssh-36_01_a09_t3 mRNA sequence1.2−1.5FG392711
Hyp21a01sh3-Domain grb2-like 2−1.51.71.3CA967895
Hyp09g14si:ch211-Protein−1.41.8CA964823
Hyp11l01Siniperca chuatsi 28S ribosomal RNA gene, partial sequence−1.51.8CA966341
Hyp24i19StAR-related lipid transfer (START) domain containing 41.4−2.11.6CA969885
Hyp09n02Sterol-c5-desaturase (fungal delta-5-desaturase) homolog (cerevisiae)−1.32.5CA964885
Hyp12p21Surfeit 4−1.51.6CA966062
Hyp20o02Tetraspanin 9−1.61.6CA965906
Hyp24i22Transaldolase 11.4−1.6CA969888
Hyp15f10Translocon-associated protein subunit delta precursor1.3−1.8CA965601
Hyp12f01Transthyretin precursor−1.33.0CA966004
Hyp07h01Triosephosphate isomerase−1.31.8CA968504
Hyp14f24Troponin c-type 21.4−2.1CA964383
Hyp21g17Troponin c-type 2−1.51.6CA967929
Hyp22g09Tubulin alpha 8 like 41.3−1.8CA969352
Hyp03o23Tubulin beta-2c1.4−1.5FG392672
Hyp17j23Tubulin beta-2c chain1.4−1.5CA965774
Hyp14f02u2 Small nuclear RNA auxiliary factor-1−1.72.41.3CA964363
Hyp22l09Vacuolar protein sorting 13c1.3−1.5CA969449
Hyp20j02Vacuolar protein sorting 4a−1.51.71.6CA966560
Hyp14j12Vimentin1.4−1.5CA964445
Hyp24i24Vimentin1.4−1.7CA969890
Hyp12i13Vitellogenin 2−1.31.4CA967775
Hyp03a21Zebrafish DNA sequence from clone ch1073-368i11 in linkage group complete sequence1.4−2.0DY231868
Hyp16n18Zebrafish DNA sequence from clone CH211-11J2 in linkage group 7, complete sequence−1.31.8CA966457
Hyp19e02Zebrafish DNA sequence from clone CH211-126C2 in linkage group 14, complete sequence−1.42.0CA965014
Hyp24p11Zebrafish DNA sequence from clone CH211-128E9 in linkage group 15, complete sequence1.4−1.6−1.8CA970016
Hyp03f11Zebrafish DNA sequence from clone ch211-132l2 in linkage group complete sequence1.4−1.7DY231843
Hyp16n17Zebrafish DNA sequence from clone CH211-134D6, complete sequence−1.31.4CF662780
Hyp09m02Zebrafish DNA sequence from clone CH211-157C7 in linkage group 7, complete sequence−1.41.7CA964874
Hyp03p21Zebrafish dna sequence from clone ch211-194m7 in linkage group 25 contains the gene for a novel proteinvertebrate ndrg family member 4 and a complete sequence1.3−1.5DY232016
Hyp19e13Zebrafish DNA sequence from clone CH211-221E5 in linkage group 8, complete sequence−1.31.5CA966187
Hyp02c11Zebrafish DNA sequence from clone ch211-271d10 in linkage group complete sequence1.4−1.5DY231543
Hyp24d22Zebrafish DNA sequence from clone CH211-286F18 in linkage group 14, complete sequence1.4−1.5CA969787
Hyp22o22Zebrafish DNA sequence from clone CH211-63O20 in linkage group 20, complete sequence1.3−1.5CA969522
Hyp24h12Zebrafish DNA sequence from clone CH211-65M8, complete sequence1.5−1.6CA969857
Hyp22j22Zebrafish DNA sequence from clone DKEY-106L3 in linkage group 10, complete sequence1.3−1.6CA969418
Hyp19m15Zebrafish DNA sequence from clone DKEY-10B15 in linkage group 10, complete sequence−1.4−1.51.8CA966228
Hyp03h21Zebrafish DNA sequence from clone dkey-13a3 in linkage group complete sequence1.4−1.5DY231928
Hyp22f11Zebrafish DNA sequence from clone DKEY-14A21 in linkage group 12, complete sequence1.4−1.7−1.6CA969332
Hyp24h11Zebrafish DNA sequence from clone DKEY-180P18 in linkage group 4, complete sequence1.8−1.9CA969856
Hyp14g09Zebrafish DNA sequence from clone DKEY-210O7 in linkage group 6, complete sequence1.5−1.4CA967264
Hyp22k16Zebrafish DNA sequence from clone DKEY-216E24 in linkage group 9, complete sequence1.3−1.4CA969432
Hyp13k21Zebrafish DNA sequence from clone DKEY-228N9 in linkage group 11, complete sequence1.3−1.6CA967861
Hyp24j22Zebrafish DNA sequence from clone DKEY-231K15 in linkage group 3, complete sequence1.3−1.6CA969909
Hyp15f02Zebrafish DNA sequence from clone DKEY-242H9 in linkage group 18, complete sequence−1.41.61.3CA965596
Hyp03i22Zebrafish DNA sequence from clone dkey-266h7 in linkage group 5 contains the 3 end of the gene for a novel proteinvertebrate mitochondrial ribosomal protein l41the gene for a novel proteinvertebrate patatin-like phospholipase domain containing 6the gene for a novel protein and the 3 end of the gene for a novel proteinvertebrate atp-binding cassette sub-family a abc1 member 2 complete sequence1.3−1.7FG392637
Hyp18b02Zebrafish DNA sequence from clone DKEY-3P10 in linkage group 23, complete sequence−1.61.6CA968927
Hyp23k09Zebrafish DNA sequence from clone DKEY-40M6 in linkage group 16, complete sequence1.3−1.5CF662916
Hyp10m12Zebrafish DNA sequence from clone DKEYP-1H4 in linkage group 18, complete sequence1.4−1.6CA967702
Hyp22p07Zebrafish DNA sequence from clone DKEYP-64A3 in linkage group 2, complete sequence−1.41.3CA969530
Hyp19o08Zinc and double phd fingers family 2−1.51.5CA965067
Hyp23a24Zinc finger ccch-type containing 7a2.0−2.3CA967982
Hyp15i14Zinc finger protein 782−1.32.0CA965639
Hyp20c13Zona pellucida glycoprotein−1.61.7CA966260
Tel12o17ccaat Enhancer-binding protein beta−1.61.7CA967804
Tel12e10Leucine-rich ppr-motif containing−1.81.6CA970240
Tel14f04Solute carrier family 2 (facilitated glucose fructose transporter) member 5−1.31.9CA964365

ESTs were manually selected based on identical AURATUS GeneIDs and on the basis of differential regulation in opposite directions for MPTP or the antagonists vs. agonists, or in the same direction for MPTP vs. antagonists.

All ESTs were identified as being statistically significantly differentially regulated (q < 5%) in all treatments. Only those with BLAST hits (NCBI), obtained with Blast2GO, are shown. In the case where a suitable BlastX hit was unavailable, the best BlastN hit is used. Duplicate names may exist in the list, but were not identified by sequence overlap (cap3) and may represent separate genes or individual isoforms. The median “minimum ExpectValue” = 1.9E−57 and the average “mean similarity” = 84.8 ± 1%.

Summary

Keywords

dopamine, sub-network enrichment analysis, neurodegeneration, reproduction, immune response

Citation

Popesku JT, Martyniuk CJ and Trudeau VL (2012) Meta-Type Analysis of Dopaminergic Effects on Gene Expression in the Neuroendocrine Brain of Female Goldfish. Front. Endocrin. 3:130. doi: 10.3389/fendo.2012.00130

Received

04 August 2012

Accepted

12 October 2012

Published

02 November 2012

Volume

3 - 2012

Edited by

Wei Ge, The Chinese University of Hong Kong, China

Reviewed by

José A. Muñoz-Cueto, University of Cadiz, Spain; Anderson O. Wong, The University of Hong Kong, Hong Kong

Copyright

*Correspondence: Jason T. Popesku, Centre for Advanced Research in Environmental Genomics, Department of Biology, University of Ottawa, Ottawa, ON, Canada K1N 6N5. e-mail: ; Vance L. Trudeau, Department of Biology, University of Ottawa, Room 160, Gendron Hall, 30 Marie Curie, Ottawa, ON, Canada K1N 6N5. e-mail:

†Present address: Jason T. Popesku, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada V6T 1Z3.

This article was submitted to Frontiers in Experimental Endocrinology, a specialty of Frontiers in Endocrinology.

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics